NCT06031285View on ClinicalTrials.gov

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sintilimab

sintilimab (200 mg intravenous infusion), a bevacizumab biosimilar (15 mg/kg intravenous infusion), and TACE-HAIC (c-TACE, FOLFOX-based HAIC).

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER